Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jan;9(1):110-6.
doi: 10.1111/j.1747-4949.2012.00894.x. Epub 2012 Sep 13.

Design and rationale of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) Trial

Affiliations
Randomized Controlled Trial

Design and rationale of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) Trial

Chelsea S Kidwell et al. Int J Stroke. 2014 Jan.

Abstract

Rationale: Multimodal imaging has the potential to identify acute ischaemic stroke patients most likely to benefit from late recanalization therapies.

Aims: The general aim of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy Trial is to investigate whether multimodal imaging can identify patients who will benefit substantially from mechanical embolectomy for the treatment of acute ischaemic stroke up to eight-hours from symptom onset.

Design: Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy is a randomized, controlled, blinded-outcome clinical trial.

Population studied: Acute ischaemic stroke patients with large vessel intracranial internal carotid artery or middle cerebral artery M1 or M2 occlusion enrolled within eight-hours of symptom onset are eligible. The study sample size is 120 patients.

Study intervention: Patients are randomized to endovascular embolectomy employing the Merci Retriever (Concentric Medical, Mountain View, CA) or the Penumbra System (Penumbra, Alameda, CA) vs. standard medical care, with randomization stratified by penumbral pattern.

Outcomes: The primary aim of the trial is to test the hypothesis that the presence of substantial ischaemic penumbral tissue visualized on multimodal imaging (magnetic resonance imaging or computed tomography) predicts patients most likely to respond to mechanical embolectomy for treatment of acute ischaemic stroke due to a large vessel, intracranial occlusion up to eight-hours from symptom onset. This hypothesis will be tested by analysing whether pretreatment imaging pattern has a significant interaction with treatment as a determinant of functional outcome based on the distribution of scores on the modified Rankin Scale measure of global disability assessed 90 days post-stroke. Nested hypotheses test for (1) treatment efficacy in patients with a penumbral pattern pretreatment, and (2) absence of treatment benefit (equivalency) in patients without a penumbral pattern pretreatment. An additional aim will only be tested if the primary hypothesis of an interaction is negative: that patients treated with mechanical embolectomy have improved functional outcome vs. standard medical management.

Keywords: MRI; clinical trial; embolectomy; ischaemic stroke; neuroimaging; penumbra.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Disclosures:

Dr. Jahan has served on the speakers’ bureau for Concentric Medical, Inc. and serves as a consultant for ev3, Inc. The University of California, Regents receive funding for Dr. Saver’s services as a scientific consultant regarding trial design and conduct to ev3 and Grifols. Drs. Jahan, Alger, Starkman, Elashoff, Gornbein, Nenov, and Saver, and Ms. Guzy are employees of the University of California, which holds a patent on Merci Retriever devices for stroke.

Figures

Figure 1
Figure 1
Study Design Flowchart

Similar articles

Cited by

References

    1. Fisher M. Characterizing the target of acute stroke therapy. Stroke. 1997;28(4):866–72. - PubMed
    1. NINDS rt-PA Stroke Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine. 1995;333:1581–7. - PubMed
    1. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 Mar 6;363(9411):768–74. - PubMed
    1. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010 May 15;375(9727):1695–703. - PubMed
    1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317–29. - PubMed

Publication types